A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) (PODO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03448692 |
Recruitment Status :
Active, not recruiting
First Posted : February 28, 2018
Last Update Posted : December 23, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Focal Segmental Glomerulosclerosis (FSGS) | Drug: PF-06730512 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 35 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Masking Description: | Open label |
Primary Purpose: | Treatment |
Official Title: | A PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) |
Actual Study Start Date : | October 15, 2018 |
Estimated Primary Completion Date : | February 13, 2023 |
Estimated Study Completion Date : | February 13, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: PF-06730512 Cohort 1
Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
|
Drug: PF-06730512
Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion. |
Experimental: PF-06730512 Cohort 2
Subjects in cohort 2 will receive dose 2 IV infusion.
|
Drug: PF-06730512
Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion. |
Experimental: PF-06730512 Cohort 3 (optional)
Subjects in cohort 3 will receive dose 3 IV infusion.
|
Drug: PF-06730512
Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion. |
- Percentage change from baseline to Week 13 in Urinary Protein to Creatinine Ratio (UPCR). [ Time Frame: Baseline to 13 weeks ]
- Percentage change from baseline in UPCR [ Time Frame: Baseline to Weeks 3, 5 and 9 and beyond Week 13, as applicable ]
- Percentage change from baseline in estimated glomerular filtration rate (eGFR) [ Time Frame: Baseline to Weeks 3, 5, 9, 13 and beyond as applicable ]
- Number of Adverse Events by Severity [ Time Frame: Baseline to Day 225 ]
- Number of subjects with laboratory safety tests (Hematology, Clinical Chemistry, Urinalysis) abnormality [ Time Frame: Baseline to Day 225 ]
- Number of subjects with change in body weight [ Time Frame: Baseline to Day 225 ]
- Number of subjects with increased blood pressure [ Time Frame: Baseline to Day 225 ]
- Number of subjects with increased body temperature [ Time Frame: Baseline to Day 225 ]
- Number of subjects with significant changes in pulse rate [ Time Frame: Baseline to Day 225 ]
- Number of subjects with ECG abnormalities [ Time Frame: Baseline to Day 225 ]
- Serum concentration of PF-06730512 [ Time Frame: Day 1 to Day 225 ]
- Number of subjects with development of anti drug antibody (ADA) and neutralizing antibody (NAb) [ Time Frame: Day 1 to Day 225 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults age 18 years and older who have a confirmed biopsy diagnosis of FSGS.
- Estimated glomerular filtration rate (eGFR) greater than or equal to 45 ml/min/1.73 m2. If eGFR is 30 - 45 ml/min/1.73 m2, a recent biopsy (within 12 months prior to Screening) must demonstrate < 50% tubulointerstitial fibrosis.
- Urine protein:creatinine ratio (UPCR) greater than 1.5 g/g at screening.
- Treated with at least one but not more than 3 classes of immunosuppressants either alone or in combination, or has a contraindication to use of an immunosuppressant or is intolerant to an immunosuppressant per investigator judgment.
Exclusion Criteria:
- Diagnosis of collapsing FSGS.
- Advanced chronic changes on renal biopsy as evidenced by greater than 50% tubulointerstitial fibrosis.
- Organ transplant.
- History of malignancy, with the exception of basal or squamous cell carcinoma that has been treated and fully resolved for a minimum of 5 years.
- Body mass index (BMI) greater than 45 kg/m2.
- Subjects with a history of prior treatment with or use of interferon, lithium, pamidronate, mTOR inhibitors (eg, sirolimus), testosterone/anabolic steroids, anthracycline (eg, doxorubicin), heroin.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03448692

Study Director: | Pfizer CT.gov Call Center | Pfizer |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT03448692 |
Other Study ID Numbers: |
C0221002 2019-003607-35 ( EudraCT Number ) ROBO2 ( Other Identifier: Alias Study Number ) PODO ( Other Identifier: Alias Study Number ) |
First Posted: | February 28, 2018 Key Record Dates |
Last Update Posted: | December 23, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
URL: | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Proteinuria |
Glomerulosclerosis, Focal Segmental Glomerulonephritis Nephritis Kidney Diseases Urologic Diseases |